Danaher Stock News

The pandemic has created a lot of noise around Danaher's revenue growth, but the dust looks set to settle in 2024. Core revenue and margins were better than expected in the second quarter.

Danaher Corporation (NYSE:DHR ) Q2 2024 Earnings Conference Call July 23, 2024 8:00 AM ET Company Participants John Bedford - VP of IR Rainer M. Blair - President & CEO Matt McGrew - EVP & CFO Conference Call Participants Jack Meehan - Nephron Research Rachel Vatnsdal - J.P.

Danaher stock flirted with a breakout Tuesday on the back of its unexpectedly strong sales from its molecular testing services.

Danaher reports second-quarter adjusted earnings of $1.72 a share on revenue of $5.74 billion.

Danaher beat Wall Street estimates for second-quarter profit and revenue on Tuesday, driven by strong demand for its genetic testing services, sending shares of the life sciences firm up nearly 8% in premarket trading.

WASHINGTON , July 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 28, 2024.  All results in this release reflect only continuing operations unless otherwise noted.

Danaher Corporation stock saw a high single-digit percentage increase from April to mid-June, but has since given up most of the gains. Concerns about inventory destocking in the bioprocessing market have impacted investor sentiment, but expectations are already priced in. Despite short-term challenges, Danaher's medium to long-term prospects remain positive, with good growth starting FY25.

DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics. Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together under a single roof.